Benralizumab reduces asthma exacerbations in severe eosinophilic asthma patients over 24 weeks.
New Asthma Shot May Cut Severe Attacks to Zero
This prospective, single-arm, multicenter, phase IV study evaluated benralizumab in 138 benralizumab-naïve adults (18–75 years) with severe …
A new injection appears safe and effective at reducing severe asthma attacks in adults.
Systematic review evaluates anti-IL-5 and anti-IL-5Rα biologics for eosinophilic respiratory and systemic diseases.
New Asthma Drugs Target the Real Troublemakers Hiding in Your Lungs
This systematic review examined the use of anti-IL-5 and anti-IL-5Rα biologics in patients with severe eosinophilic asthma, chronic rhinosin…
New asthma drugs target the specific immune cells causing swelling and mucus in severe asthma, nasal polyps, and rare eosinophil diseases.